Menu Search
Equities

Eris Lifesciences Ltd

ERIS:NSI

Eris Lifesciences Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,374.20
  • Today's Change6.20 / 0.45%
  • Shares traded35.62k
  • 1 Year change+45.11%
  • Beta0.7325
Data delayed at least 15 minutes, as of Nov 22 2024 09:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Eris Lifesciences Ltd had little change in net income (from 3.82bn to 3.92bn) despite revenues that grew 19.23% from 16.85bn to 20.09bn.
Gross margin77.03%
Net profit margin14.69%
Operating margin23.31%
Return on assets6.73%
Return on equity13.45%
Return on investment8.39%
More ▼

Cash flow in INRView more

In 2024, Eris Lifesciences Ltd increased its cash reserves by 68.23%, or 382.23m. Cash Flow from Financing totalled 13.80bn or 68.68% of revenues. In addition the company generated 5.13bn in cash from operations while cash used for investing totalled 18.55bn.
Cash flow per share45.72
Price/Cash flow per share29.87
Book value per share203.74
Tangible book value per share-147.79
More ▼

Balance sheet in INRView more

Eris Lifesciences Ltd has a Debt to Total Capital ratio of 46.26%, a higher figure than the previous year's 26.23%.
Current ratio1.07
Quick ratio0.8599
Total debt/total equity0.9868
Total debt/total capital0.4626
More ▼

Growth rates in INR

Year on year, growth in earnings per share excluding extraordinary items increased 2.57%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)6.38
EPS (TTM) vs
TTM 1 year ago		-9.67
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.